Humanigen, Inc. (HGEN): Price and Financial Metrics

Humanigen, Inc. (HGEN): $2.37

0.16 (+7.24%)

POWR Rating

Component Grades













Add HGEN to Watchlist
Sign Up

Industry: Biotech


of 455

in industry


  • Quality is the dimension where HGEN ranks best; there it ranks ahead of 30.06% of US stocks.
  • The strongest trend for HGEN is in Value, which has been heading down over the past 169 days.
  • HGEN's current lowest rank is in the Stability metric (where it is better than 3.61% of US stocks).

HGEN Stock Summary

  • Revenue growth over the past 12 months for Humanigen Inc comes in at 259.65%, a number that bests 96.86% of the US stocks we're tracking.
  • The volatility of Humanigen Inc's share price is greater than that of 98.96% US stocks with at least 200 days of trading history.
  • Humanigen Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -113.83%, greater than the shareholder yield of only 3.62% of stocks in our set.
  • Stocks that are quantitatively similar to HGEN, based on their financial statements, market capitalization, and price volatility, are AUTL, VCNX, ERYP, ORGS, and VNE.
  • HGEN's SEC filings can be seen here. And to visit Humanigen Inc's official web site, go to

HGEN Valuation Summary

  • In comparison to the median Healthcare stock, HGEN's price/sales ratio is 4632.16% higher, now standing at 537.1.
  • Over the past 104 months, HGEN's price/earnings ratio has gone up 1.2.
  • Over the past 104 months, HGEN's price/sales ratio has gone up 531.9.

Below are key valuation metrics over time for HGEN.

Stock Date P/S P/B P/E EV/EBIT
HGEN 2021-08-31 537.1 22.5 -4.9 -4.5
HGEN 2021-08-30 543.5 22.8 -5.0 -4.5
HGEN 2021-08-27 563.3 23.6 -5.2 -4.7
HGEN 2021-08-26 577.5 24.2 -5.3 -4.8
HGEN 2021-08-25 570.1 23.9 -5.2 -4.8
HGEN 2021-08-24 559.4 23.5 -5.1 -4.7

HGEN Growth Metrics

    The 2 year price growth rate now stands at 628.57%.
  • The 4 year price growth rate now stands at 45.71%.
  • Its 4 year cash and equivalents growth rate is now at -98.84%.
HGEN's revenue has moved up $2,870,000 over the prior 15 months.

The table below shows HGEN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 2.87 -175.481 -235.404
2021-06-30 1.834 -151.022 -199.416
2021-03-31 0.798 -105.07 -152.635
2020-12-31 0.312 -69.853 -89.535
2020-09-30 0 -46.707 -59.266
2020-06-30 0 -24.343 -30.904

HGEN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HGEN has a Quality Grade of C, ranking ahead of 29.47% of graded US stocks.
  • HGEN's asset turnover comes in at 0.019 -- ranking 371st of 682 Pharmaceutical Products stocks.
  • ZSAN, ARMP, and AGRX are the stocks whose asset turnover ratios are most correlated with HGEN.

The table below shows HGEN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.019 1 9.745
2021-03-31 0.011 1 9.024
2020-12-31 0.006 1 6.758
2020-09-30 0.000 NA 5.896
2020-06-30 0.000 NA 3.998
2020-03-31 0.000 NA 1.549

HGEN Price Target

For more insight on analysts targets of HGEN, see our HGEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $21.13 Average Broker Recommendation 1.67 (Moderate Buy)

HGEN Stock Price Chart Interactive Chart >

Price chart for HGEN

HGEN Price/Volume Stats

Current price $2.37 52-week high $29.20
Prev. close $2.21 52-week low $2.14
Day low $2.15 Volume 1,069,255
Day high $2.38 Avg. volume 1,369,387
50-day MA $4.17 Dividend yield N/A
200-day MA $11.54 Market Cap 151.25M

Humanigen, Inc. (HGEN) Company Bio

Humanigen, Inc., a clinical stage biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes granulocyte-macrophage colony-stimulating factor, which is in Phase Ib/II clinical trial in patients with chronic myelomonocytic leukemia, and for the treatment of juvenile myelomonocytic leukemia. It also develops Ifabotuzumab, a monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005 an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic diseases. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.

HGEN Latest News Stream

Event/Time News Detail
Loading, please wait...

HGEN Latest Social Stream

Loading social stream, please wait...

View Full HGEN Social Stream

Latest HGEN News From Around the Web

Below are the latest news stories about Humanigen Inc that investors may wish to consider to help them evaluate HGEN as an investment opportunity.

Humanigen: New Publication Details Lenzilumab’s Economic Benefits, Says Analyst

So many stocks have taken a beating recently, leaving plenty of analysts’ predictions for the coming year looking very bullish indeed. However, there are possibly only a select few – if any - more optimistic than H.C. Wainwright’s Joseph Pantginis outlook for Humanigen (HGEN) stock. It’s true this name has been shredded to pieces over the past 12 months, with shares now at an 87% discount compared to a year ago. Still, backing up his Buy rating, the analyst’s $28 price target suggests the stock will climb by 941%.

Marty Shtrubel on TipRanks | January 19, 2022

Humanigen: New Publication Details Lenzilumabs Economic Benefits, Says Analyst

So many stocks have taken a beating recently, leaving plenty of analysts predictions for the coming year looking very bullish indeed. However, there are possibly o

TipRanks | January 19, 2022

Humanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating the Clinical and Economic Benefits of Lenzilumab

BURLINGAME, Calif., January 18, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced a peer-reviewed publication in the Journal of Medical Economics ( citing the clinical and associated health economic benefits of lenzilumab. The publication demonstrated, in all cases, lenzilumab plus SOC

Yahoo | January 18, 2022

Analysts Offer Insights on Healthcare Companies: and Humanigen (HGEN)

There's a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and Humanigen (HGEN – Research Report) with bullish sentiments. Humanigen (HGEN) H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Humanigen on January 5 and set a price target of $28.00. The company's shares closed last Tuesday at $3.22. According to TipRanks.

Christine Brown on TipRanks | January 12, 2022

Wall Street Analysts Are Bullish on Top Healthcare Picks

There's a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and Humanigen (HGEN – Research Report) with bullish sentiments. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Read More on HGEN: Adamis Pharma Updates 1 Key Risk Factor Wall Street Analysts Are Bullish on Top Materials Picks Analysts’ Top Conglomerates Picks: Acuity Brands (AYI) Analysts Offer Insights on Technology Companies: and VerifyMe (VRME) Surmodics, Inc.

Christine Brown on TipRanks | January 12, 2022

Read More 'HGEN' Stories Here

HGEN Price Returns

1-mo -35.25%
3-mo -66.99%
6-mo -85.30%
1-year -87.06%
3-year -45.52%
5-year -83.19%
YTD -36.29%
2021 -78.74%
2020 617.95%
2019 -30.36%
2018 73.91%
2017 -89.68%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9424 seconds.